TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03764449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Balovaptan
Description: In Period 1, balovaptan was administered as a single oral dose.~In Period 2, balovaptan was administered as an oral dose once daily on Day 1 to Day 14.
Study: NCT01950988

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush Broscyl®

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush Broscyl®

Intervention type: DEVICE
Group type: OTHER
Intervention: Manual toothbrush Broscyl®
Study: NCT00712595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Oral administration of Mifepristone 10 mg daily for three months
Study: NCT00712595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Oral administration of Mifepristone 5 mg, daily for three months
Study: NCT01637454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terlipressin
Description: Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
Study: NCT04439214

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT04164108

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Intermittent Enteral Nutrition Protocol
Description: Patients will receive total recommended nutrition divided into four equal meals, delivered at a rate of 400 cc/hr at 8:00, 12:00, 16:00, 20:00. Titration schedule will include administering 50% of volume for first two feeds, then 75%, and then 100%.
Study: NCT01356043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-amlodipine 5mg,Telmisartan 80mg
Description: S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S-amlodipine 5mg
Description: S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
Study: NCT03862131

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MyoStrain®
Description: MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoStrain®
Description: MyoStrain® SENC software receives image data from MRI storage archives and performs viewing, image manipulation, communication, printing, and quantification of images.
Study: NCT00776295

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes
Description: Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
Study: NCT02589990

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: see arm description
Study: NCT00060203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brostallicin
Description: Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.~Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity.
Study: NCT00860197

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fully torrefied coffee
Description: Fully torrefied coffee

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Partially torrefied coffee
Description: Partially torrefied coffee
Study: NCT00557011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRP104
Description: 30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adderall XR
Description: 10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule taken once daily in the morning
Study: NCT00875108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIAject™
Description: Subcutaneous injection 25 IU/mL
Study: NCT03183089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rohto Dry-Aid®
Study: NCT03764449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Balovaptan
Description: In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Balovaptan
Description: In Period 1, IV infusion of balovaptan was administered after the balovaptan oral dose.~In Period 2, IV infusion of balovaptan was administered after the final oral dose of balovaptan.
Study: NCT00169000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1~Dose level -2 600 mg/m2 po BID~Dose level -1 700 mg/m2 po BID~Dose level 1 825 mg/m2 po BID~Dose level 2 1000 mg/m2 po BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 over one hour on day 8 of each cycle
Study: NCT00379522

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasopressin
Description: 10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: Placebo for arginine vasopressin
Study: NCT03362359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ga-68-PSMA-11
Description: Single administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg. A 2nd administration of 150 MBq (± 50 MBq), corresponding to a mass dose of ≤ 6 µg is possible in the unlikely case of a negative histological result (i.e. no prostate-specific membrane antigen (PSMA) expression in dissected lymph nodes) to verify if PSMA PET-positive tissue as seen on day 1 has not been removed during RP with EPLND.
Study: NCT01370525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Esomeprazole
Description: Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
Study: NCT03376867

Intervention type: OTHER
Intervention: Conditioned pain modulation
Description: Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.

Intervention type: OTHER
Intervention: Conditioned pain modulation
Description: Conditioned pain modulation (CPM) protocol consist of evaluating pain during two stimuli test (heat and pressure point), before and after one conditioning stimulus (cold water bath); Blood analyses for biochemistry and genes polymorphisms.
Study: NCT01705496

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: [124I]FIAU
Description: This is a single dose study of 5 mCi \[124I\]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after \[124I\]FIAU injection.
Study: NCT03159520

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice sheet
Description: Advice on management of post orthodontic pain

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advice sheet
Description: Advice on management of post orthodontic pain
Study: NCT00498979

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa-2b
Description: recombinant interferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: recombinant interferon alfa-2b

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium stibogluconate
Description: sodium stibogluconate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: dacarbazine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: vinblastine
Study: NCT00415610

Intervention type: DRUG
Group type: OTHER
Intervention: nicardipine
Description: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.

Intervention type: DRUG
Group type: OTHER
Intervention: nicardipine
Description: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.

Intervention type: DRUG
Group type: OTHER
Intervention: nicardipine
Description: Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.~* Started at 5mg/h~* Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour \*Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued.
Study: NCT04224324

Intervention type: PROCEDURE
Intervention: Tonsillectomy and Adeniodectomy
Description: pediatric patients undergoing tonsillectomy and adenoidectomy
Study: NCT03087344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan and Acoustic Radiation Force Impulse
Description: Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
Study: NCT02491788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suvorexant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02444559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 20ml 5mg/ml+ Clonidine 150ug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine 20ml 5mg/ml+ Placebo
Study: NCT00679783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: PARP inhibitor Olaparib tablets, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: PARP inhibitor Olaparib tablets, oral
Study: NCT03087344

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: Liver stiffness will be measured before and after a standard meal is administered

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acoustic Radiation Force Impulse
Description: Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
Study: NCT00679783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2281
Description: PARP inhibitor Olaparib tablets, oral
Study: NCT04030858

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Plant-based diet + nutrition education
Description: The intervention group will adopt a nutrient-dense dietary pattern and receive nutrition education sessions specific to that lifestyle. The diet protocol is comprised of minimally-processed plant foods such as fruits, vegetables, legumes, beans, nuts and seeds. No refined sugars, added salt, or oil will be included. Dietary fat intake limited to 20% of total calories or less per day. Animal products will be eliminated. This dietary pattern is expected to improve resilience, mood, inflammation, microbiome, spirituality, and overall general health (as measured by weight, cholesterol, blood pressure). The treatment group will also receive weekly nutrition education sessions to support the diet.
Study: NCT04028349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV/MVA-BN-Filo
Description: Candidate Ebola Vaccine
Study: NCT00964834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline and Valortim
Description: Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Valortim
Description: Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
Study: NCT03183089

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systane® Ultra
Study: NCT03813836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Patients will receive best supportive care + pembrolizumab 200mg every 3 weeks for a maximum duration of 24 months
Study: NCT00964834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Antibiotic and Placebo Valortim
Description: Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
Study: NCT03239860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1 Monoclonal Antibody
Description: Monthly IV
Study: NCT03067454

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Early mobilisation
Description: Conservative treatment with early mobilisation~The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operation
Description: Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
Study: NCT00877084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: usual care according to clinical pathway for COPD, No training
Study: NCT01479998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: standard care
Description: standard care plus nicotine replacement therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard care plus contingency management
Description: standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
Study: NCT02300857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High carbohydrate diet
Description: Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
Study: NCT03239860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1 Monoclonal Antibody
Description: Monthly IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GNbAC1 Monoclonal Antibody
Description: Monthly IV
Study: NCT02449382

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous venovenous hemofiltration
Description: If the serum sodium concentration \>150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
Study: NCT03612648

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Three Fraction Accelerated Partial Breast Irradiation
Description: * TRI-APBI simulation must take place no more than 8 weeks from final definitive breast surgery~* Machines that could be used include: SAVI applicator, The ViewRay System for Radiation Therapy, The ViewRay (MRIdian) Linac System, Halcyon, True Beam, True Beam STx, Edge Radiotherapy Delivery System

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Partial mastectomy
Description: -Standard of Care
Study: NCT01267292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: \[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Buspirone
Description: \[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\] \[weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Methylphenidate serves as an acute stimulant challenge. \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo for Methylphenidate
Description: \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for Methylphenidate
Description: \[week 1: no Methylphenidate or Methylphenidate placebo\] \[week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\] \[week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)\]
Study: NCT03238898

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin type A
Description: botulinum toxin type A injections~Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline injections~The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps.
Study: NCT04074421

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifaximin
Description: A non-aminoglycoside intestinal antibiotic, 400mg, twice one day for 2 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Probiotic Formula
Description: A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo oral tablet that has no therapeutic effect
Study: NCT00766233

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermal treatment
Description: Hyperthermal treatment one or three times per week for 60 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperthermal treatment
Description: Hyperthermal treatment one or three times per week for 60 minutes
Study: NCT02459262

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GBS-NN vaccine
Description: Three dose levels will be administered, with and without Alhydrogel®

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: GBS-NN vaccine
Description: Three dose levels will be administered, with and without Alhydrogel®
Study: NCT03925701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: vildagliptin twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vildagliptin\metformin
Description: vildagliptin\\metformin twice daily
Study: NCT03916432

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HELIOS biodegradable polymer sirolimus-eluting stents
Description: HELIOS biodegradable polymer sirolimus-eluting stents